Amazon, EWPanel, Shine, RPRD & More: This Week’s Wisconsin Watchlist

(Page 2 of 2)

involved charging other healthcare software companies to use Redox’s data-integration tools.

—Janesville-based Shine Medical Technologies raised nearly $6.9 million in debt financing from 26 investors, according to a document filed with federal securities regulators. Shine is seeking to resume domestic manufacturing of an isotope that is in turn used to produce technetium-99m, the most widely used radioisotope in medical diagnostic imaging. The company recently broke ground on an 11,500-square-foot prototype production facility, where it will test its particle accelerator-based technology for producing isotopes.

—The Milwaukee-based pharmacogenetics startup Right Patient Right Drug (RPRD) Diagnostics announced a collaboration with Orient Bio, a biotech company based in South Korea. RPRD is developing technology to examine how patients’ genetic profiles affect their likelihood of reacting to particular drugs. The startup said in a press release that Orient Bio is particularly interested in a panel developed by RPRD that’s highly relevant for patients of East Asian ethnicity who may receive thiopurine drug treatment, prescribed for patients with leukemia and other diseases.

Single PageCurrently on Page: 1 2 previous page

Jeff Buchanan is the editor of Xconomy Seattle. Email: jbuchanan@xconomy.com Follow @_jeffbuchanan

Trending on Xconomy